Ryufin

Getinge AB (publ)

Sweden · SE0000202624 · reports in SEK · Europe

The answers

From the annual report for the year to Dec 31, 2024. Each line says what it is based on.

Is it growing?Fair
Revenue +9.2% in the year to Dec 31, 2024, on the year before.
Is it a good business?To watch
It earned 5.0% on its shareholders' equity in the year to Dec 31, 2024.
Is it safe?Good
Equity is 52% of its assets, and operations brought in cash in the year.
Is the price fair?n/a
Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.

The year

Year to Dec 31, 2024, consolidated, in SEK.

SEK 34.8B

revenue

8.2%

operating margin

SEK 1.6B

net profit

Year by year

As filed; an earlier year can differ from its own report when the company restated it.

Dec 2021Dec 2022Dec 2023Dec 2024
RevenueSEK 27.0BSEK 28.3BSEK 31.8BSEK 34.8B
Operating profitSEK 4.4BSEK 3.6BSEK 3.7BSEK 2.9B
Net profit to shareholdersSEK 3.0BSEK 2.5BSEK 2.4BSEK 1.6B
Earnings per shareSEK 10.90SEK 9.15SEK 8.86SEK 6.01
Dividend per sharen/aSEK 4.00n/aSEK 4.40
Cash from operationsSEK 6.6BSEK 3.4BSEK 3.0BSEK 4.6B
CashSEK 4.1BSEK 5.7BSEK 2.7BSEK 3.0B
Total assetsSEK 44.6BSEK 52.0BSEK 53.6BSEK 63.9B
EquitySEK 25.2BSEK 30.5BSEK 30.4BSEK 33.2B

What they do

In the company's own words, from the annual report.

Getinge är en global leverantör av produkter och tjänster för kirurgi, intensivvård och infektionsbekämpning med verksamhet i 40 länder och egen produktion i 9 länder. Verksamheten bedrivs inom tre affärsområden – Acute Care Therapies, Life Science och Surgical Workflows.

Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.